August 28, 2007 5:00 PM
- Text
Nasal Spray May Ease Cluster Headaches
- Adele's Grammy Comeback After Vocal Cord Surgery
- Treating Sleep Apnea in Kids Improves Behavior, Quality of Life
- Chemo May Not Harm Unborn Baby
- C-Sections Not Always Best for Small Babies
- CDC: Doctors Increasingly Prescribe Exercise
- Osteoporosis Medication Linked to Unusual Thigh Fractures
- More from WebMD »
Migranes, stress illness headache ache, heart line, halth (CBS/AP)
(WebMD)
The prescription nasal spray Zomig, which is used to treat migraines, may ease cluster headaches.
That's according to a new study published in today's edition of the journal Neurology.
Cluster headache, which is a severe type of headache disorder, affects less than 1 percent of the public, note the researchers, who included Alan Rapoport, M.D., of The New England Center for Headache in Stamford, Conn. Rapoport and colleagues studied 52 adults aged 23-65 (average age: 45) who had cluster headaches.
Rapoport's team gave each patient a nasal spray. Some patients got sprays containing 5 milligrams of Zomig. Others got a 10-milligram Zomig spray. For comparison, a third group of patients got a spray containing no medicine.
The patients didn't know whether their nasal spray contained Zomig. They were told to use their nasal spray when a cluster headache began. Patients reported how long their cluster headaches lasted. Both doses of Zomig trumped the placebo.
For instance, half an hour after cluster headaches started, headache relief was reported by 63 percent of patients using the 10-milligram Zomig spray, 50 percent of those using the 5-milligram Zomig spray, and 30 percent of those using the placebo spray.
Patients using the Zomig nasal sprays were more likely than those using the placebo spray to report side effects. Those side effects - which included discomfort in the nasal cavity, bad taste, dizziness, sleepiness, nausea, and tightness in the throat, chest, and neck - were typical of Zomig's class of drugs, according to the researchers.
Zomig isn't approved by the FDA to treat cluster headaches, Rapoport and colleagues warn. They point out that the only drug currently approved by the FDA to treat cluster headaches is injectable Imitrex, which is also used to treat migraines.
Rapoport's study was funded by AstraZeneca, the drug company that makes Zomig.
By Miranda Hitti
Reviewed by Louise Chang, M.D.
©2007 WebMD, Inc. All rights reserved
That's according to a new study published in today's edition of the journal Neurology.
Cluster headache, which is a severe type of headache disorder, affects less than 1 percent of the public, note the researchers, who included Alan Rapoport, M.D., of The New England Center for Headache in Stamford, Conn. Rapoport and colleagues studied 52 adults aged 23-65 (average age: 45) who had cluster headaches.
Rapoport's team gave each patient a nasal spray. Some patients got sprays containing 5 milligrams of Zomig. Others got a 10-milligram Zomig spray. For comparison, a third group of patients got a spray containing no medicine.
The patients didn't know whether their nasal spray contained Zomig. They were told to use their nasal spray when a cluster headache began. Patients reported how long their cluster headaches lasted. Both doses of Zomig trumped the placebo.
For instance, half an hour after cluster headaches started, headache relief was reported by 63 percent of patients using the 10-milligram Zomig spray, 50 percent of those using the 5-milligram Zomig spray, and 30 percent of those using the placebo spray.
Patients using the Zomig nasal sprays were more likely than those using the placebo spray to report side effects. Those side effects - which included discomfort in the nasal cavity, bad taste, dizziness, sleepiness, nausea, and tightness in the throat, chest, and neck - were typical of Zomig's class of drugs, according to the researchers.
Zomig isn't approved by the FDA to treat cluster headaches, Rapoport and colleagues warn. They point out that the only drug currently approved by the FDA to treat cluster headaches is injectable Imitrex, which is also used to treat migraines.
Rapoport's study was funded by AstraZeneca, the drug company that makes Zomig.
By Miranda Hitti
Reviewed by Louise Chang, M.D.
©2007 WebMD, Inc. All rights reserved
Popular Now in Health
- Cancer drug reverses Alzheimer's in mice: Study
- Norovirus outbreak hits Rider University in N.J
- Marijuana-smoking motorists twice as likely to crash
- Electric shocks to brain may boost memory: Study
- America's pets also have an obesity epidemic
- 4.5 million Americans over 50 have artificial knees
- Skin cancer self-exam: What to look for (PHOTOS)
- Caffeine inhalers - the next club drug?
- Measles patient at Super Bowl prompts health alert
- America's sodium problem: Not from salty snacks?
- Chinese mom gives birth to 15-pound baby
- Things You Didn't Know About Your Penis
- PICTURES: 15 Shocking Sexual Fetishes
- Let's Move! campaign turns 2 today: Is it working?
- John Dye Dies: What Killed "Angel" Star?
- Woman spotlights uterus didelphys on talk show
- Christina Hendricks: Too Big for Hollywood?
Latest CBS News Headlines
on Facebook
on CBS News
- Unions expect right-to-work will cost them members
- Cops: Accused pimp solicits bail via Facebook
- US sex abuse lawsuit against Vatican dismissed
- US sex abuse lawsuit against Vatican dismissed
on Facebook
- Adele sings a cappella for Anderson Cooper
- Occupy protestors kicked out of CPAC
- CPAC: Will Sarah Palin spring a surprise?
- Beyonce and Jay-Z post first photos of Blue Ivy Carter
on CBS News






